Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. JNJ
stocks logo

JNJ

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
22.85B
+1.78%
2.680
-4.96%
23.10B
+2.8%
2.688
+11.06%
23.46B
+4.17%
2.484
+21.76%
Estimates Revision
The market is revising Upward the revenue expectations for Johnson & Johnson (JNJ) for FY2025, with the revenue forecasts being adjusted by 1.36% over the past three months. During the same period, the stock price has changed by -6.42%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.36%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.21%
In Past 3 Month
Stock Price
Go Down
down Image
-6.42%
In Past 3 Month
15 Analyst Rating
up Image0
Wall Street analysts forecast JNJ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 171.79 USD with a low forecast of 159.00 USD and a high forecast of 185.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
8 Hold
0 Sell
Moderate Buy
up Image0
Current: 152.380
sliders
Low
159.00
Averages
171.79
High
185.00
up Image0
Current: 152.380
sliders
Low
159.00
Averages
171.79
High
185.00
Leerink
Outperform -> Market Perform
downgrade
$169 -> $153
2025-05-13
Reason
Leerink
Price Target
$169 -> $153
2025-05-13
downgrade
Outperform -> Market Perform
Reason
Leerink downgraded Johnson & Johnson to Market Perform from Outperform with a price target of $153, down from $169, after CMS issued draft guidance for 2028 IRA drug price controls that creates risk that hyaluronidase combination products may not be protected from IRA price negotiations for 13 years after combo approval. The "surprise" is that CMS draft guidance language suggests that combination products that do not enhance efficacy may be negotiated 13 years after the original active ingredient was approved, rather than 13 years after combination approval, the analyst tells investors.
Barclays
Matt Miksic
Hold
Maintains
$166 → $165
2025-04-17
Reason
Barclays
Matt Miksic
Price Target
$166 → $165
2025-04-17
Maintains
Hold
Reason
Barclays lowered the firm's price target on Johnson & Johnson to $165 from $166 and keeps an Equal Weight rating on the shares following the Q1 report. The company reported strong Pharma results offset by slower growth in MedTech, driven primarily by a series of one-timers and prior year issues, the analyst tells investors in a research note. The firm says J&J maintained its 2025 outlook despite additional deal dilution and tariff impact.
Raymond James
Jayson Bedford
Buy
Maintains
$162 → $164
2025-04-16
Reason
Raymond James
Jayson Bedford
Price Target
$162 → $164
2025-04-16
Maintains
Buy
Reason
Raymond James analyst Jayson Bedford lowered the firm's price target on Johnson & Johnson to $162 from $165 and keeps an Outperform rating on the shares ahead of quarterly results. While a portion of the tariff drama was dampened last Wednesday, the firm still expects Q1 MedTech earnings season to be eventful. The uncertainty tied to the impact of tariffs has tightened investment decisions, reduced the appetite for risk, and weighed on MedTech multiples. Based on Raymond James' math, the market is baking in an 8% cut to annual EPS for its large cap coverage. While the firm acknowledges a heightened level of uncertainty, its initial view is that this seems excessive.
Morgan Stanley
Terence Flynn
Hold
Maintains
$164 → $169
2025-04-16
Reason
Morgan Stanley
Terence Flynn
Price Target
$164 → $169
2025-04-16
Maintains
Hold
Reason
Morgan Stanley raised the firm's price target on Johnson & Johnson to $164 from $163 and keeps an Equal Weight rating on the shares. The firm adjusted its large cap pharma and biotech models for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting season for the group.
RBC Capital
Shagun Singh
Buy
Reiterates
$181
2025-04-16
Reason
RBC Capital
Shagun Singh
Price Target
$181
2025-04-16
Reiterates
Buy
Reason
Raymond James
Jayson Bedford
Buy
Maintains
$165 → $162
2025-04-14
Reason
Raymond James
Jayson Bedford
Price Target
$165 → $162
2025-04-14
Maintains
Buy
Reason
Raymond James analyst Jayson Bedford lowered the firm's price target on Johnson & Johnson to $162 from $165 and keeps an Outperform rating on the shares ahead of quarterly results. While a portion of the tariff drama was dampened last Wednesday, the firm still expects Q1 MedTech earnings season to be eventful. The uncertainty tied to the impact of tariffs has tightened investment decisions, reduced the appetite for risk, and weighed on MedTech multiples. Based on Raymond James' math, the market is baking in an 8% cut to annual EPS for its large cap coverage. While the firm acknowledges a heightened level of uncertainty, its initial view is that this seems excessive.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Johnson & Johnson (JNJ.N) is 14.92, compared to its 5-year average forward P/E of 16.27. For a more detailed relative valuation and DCF analysis to assess Johnson & Johnson 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
16.27
Current PE
14.92
Overvalued PE
17.40
Undervalued PE
15.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
12.99
Current EV/EBITDA
11.74
Overvalued EV/EBITDA
13.77
Undervalued EV/EBITDA
12.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
4.49
Current PS
4.05
Overvalued PS
4.81
Undervalued PS
4.17

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

JNJ News & Events

Events Timeline

(ET)
2025-06-17
09:58:26
Trump administration weighs crackdown on pharma ads, Bloomberg says
select
2025-06-15 (ET)
2025-06-15
20:16:29
Johnson & Johnson announces new results from Phase 2 RedirecTT-1 study
select
2025-06-13 (ET)
2025-06-13
11:06:04
Johnson & Johnson announces clinical data from Phase 1b study of JNJ-4496
select
Sign Up For More Events
Sign Up For More Events

News

Preview
9.0
06-15Newsfilter
PinnedInvestigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

  • Study Results: The Phase 2 RedirecTT-1 study revealed a high overall response rate of 78.9% in patients with relapsed/refractory multiple myeloma using the combination of TALVEY® and TECVAYLI®, particularly benefiting those with extramedullary disease who have limited treatment options.

  • Safety Profile: The safety profile of the combination therapy was consistent with previous reports, showing low rates of adverse events and allowing for improved dosing schedules, indicating a promising treatment option for patients with advanced multiple myeloma.

Preview
9.0
06-15Yahoo Finance
PinnedInvestigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

  • Study Results: The Phase 2 RedirecTT-1 study shows a promising overall response rate of 78.9% in patients with relapsed/refractory multiple myeloma and extramedullary disease using the bispecific antibodies TALVEY and TECVAYLI, indicating potential for improved treatment options in this challenging patient population.

  • Safety Profile: The combination therapy demonstrated a safety profile consistent with previous reports, with low rates of severe adverse events and manageable side effects, suggesting it could be a viable treatment alternative for heavily pretreated patients.

Preview
8.0
05:16 AMYahoo Finance
Trump's big beautiful bill: What the pharma industry is watching

  • Pharmaceutical Stocks Decline: Major pharmaceutical companies like Pfizer, Johnson & Johnson, and Abbvie are experiencing stock declines following President Trump's announcement of impending tariffs on the industry.

  • Healthcare Policy Insights: Chris Meekins discusses potential impacts of healthcare legislation, highlighting changes to Medicaid provider taxes and the implications for state budgets, while expressing skepticism about the accuracy of CBO enrollment projections.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Johnson & Johnson (JNJ) stock price today?

The current price of JNJ is 152.38 USD — it has decreased -1.83 % in the last trading day.

arrow icon

What is Johnson & Johnson (JNJ)'s business?

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. The Company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolism. Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, cardiovascular, and vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eyecare professionals, and clinics.

arrow icon

What is the price predicton of JNJ Stock?

Wall Street analysts forecast JNJ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 171.79 USD with a low forecast of 159.00 USD and a high forecast of 185.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Johnson & Johnson (JNJ)'s revenue for the last quarter?

Johnson & Johnson revenue for the last quarter amounts to 21.89B USD, increased 2.39 % YoY.

arrow icon

What is Johnson & Johnson (JNJ)'s earnings per share (EPS) for the last quarter?

Johnson & Johnson. EPS for the last quarter amounts to 4.54 USD, increased 238.81 % YoY.

arrow icon

What changes have occurred in the market's expectations for Johnson & Johnson (JNJ)'s fundamentals?

The market is revising Upward the revenue expectations for Johnson & Johnson (JNJ) for FY2025, with the revenue forecasts being adjusted by 1.36% over the past three months. During the same period, the stock price has changed by -6.42%.
arrow icon

How many employees does Johnson & Johnson (JNJ). have?

Johnson & Johnson (JNJ) has 138100 emplpoyees as of June 18 2025.

arrow icon

What is Johnson & Johnson (JNJ) market cap?

Today JNJ has the market capitalization of 366.64B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free